Search research articles
Contact Us
Filters
Showing results (41-50 of 89) with videos related to
Page
of 9
Sort By:
Revue Des Maladies Respiratoires
|
February 17, 2020
[Management of right ventricular failure in pulmonary vascular diseases]
A Boucly, L Savale, C Vuillard, et al.
The European Respiratory Journal
|
November 10, 2009
Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension
B Sztrymf, R Souza, L Bertoletti, et al.
Revue Des Maladies Respiratoires
|
February 1, 2023
[Lung transplantation for severe pulmonary hypertension]
J Le Pavec, L Savale, G Prévot, et al.
Circulation
|
November 15, 2000
Improvement of von Willebrand factor proteolysis after prostacyclin infusion in severe pulmonary arterial hypertension
A Veyradier, T Nishikubo, M Humbert, et al.
Thorax
|
October 18, 2005
Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis
H Nunes, M Humbert, F Capron, et al.
The European Respiratory Journal
|
September 4, 1998
Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension
O Sitbon, M Humbert, J L Jagot, et al.
La Revue De Medecine Interne
|
September 4, 2018
[Liver diseases and pulmonary vascular disorders]
M Riou, E-M Jutant, X Mignard, et al.
Revue Des Maladies Respiratoires
|
February 27, 2022
[Hepatopulmonary syndrome: Prevalence, pathophysiology and clinical implications]
M-C Certain, F Robert, A Baron, et al.
The European Respiratory Journal
|
August 13, 1999
Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study
M Humbert, O Sanchez, M Fartoukh, et al.
American Journal of Respiratory and Critical Care Medicine
|
February 1, 1995
Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin
O Sitbon, F Brenot, A Denjean, et al.
Page
of 9
Search research articles
Search
Showing results (41-50 of 89) with videos related to
Sort By:
Page
of 9
Revue Des Maladies Respiratoires
|
February 17, 2020
[Management of right ventricular failure in pulmonary vascular diseases]
A Boucly, L Savale, C Vuillard, et al.
The European Respiratory Journal
|
November 10, 2009
Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension
B Sztrymf, R Souza, L Bertoletti, et al.
Revue Des Maladies Respiratoires
|
February 1, 2023
[Lung transplantation for severe pulmonary hypertension]
J Le Pavec, L Savale, G Prévot, et al.
Circulation
|
November 15, 2000
Improvement of von Willebrand factor proteolysis after prostacyclin infusion in severe pulmonary arterial hypertension
A Veyradier, T Nishikubo, M Humbert, et al.
Thorax
|
October 18, 2005
Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis
H Nunes, M Humbert, F Capron, et al.
The European Respiratory Journal
|
September 4, 1998
Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension
O Sitbon, M Humbert, J L Jagot, et al.
La Revue De Medecine Interne
|
September 4, 2018
[Liver diseases and pulmonary vascular disorders]
M Riou, E-M Jutant, X Mignard, et al.
Revue Des Maladies Respiratoires
|
February 27, 2022
[Hepatopulmonary syndrome: Prevalence, pathophysiology and clinical implications]
M-C Certain, F Robert, A Baron, et al.
The European Respiratory Journal
|
August 13, 1999
Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study
M Humbert, O Sanchez, M Fartoukh, et al.
American Journal of Respiratory and Critical Care Medicine
|
February 1, 1995
Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin
O Sitbon, F Brenot, A Denjean, et al.
Page
of 9